170 related articles for article (PubMed ID: 9836559)
1. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer.
Mackey TJ; Borkowski A; Amin P; Jacobs SC; Kyprianou N
Urology; 1998 Dec; 52(6):1085-90. PubMed ID: 9836559
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x.
Pollack A; Cowen D; Troncoso P; Zagars GK; von Eschenbach AC; Meistrich ML; McDonnell T
Cancer; 2003 Apr; 97(7):1630-8. PubMed ID: 12655519
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
[TBL] [Abstract][Full Text] [Related]
4. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer.
Scopa CD; Vagianos C; Kardamakis D; Kourelis TG; Kalofonos HP; Tsamandas AC
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):329-34. PubMed ID: 11759059
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers.
Krajewska M; Krajewski S; Epstein JI; Shabaik A; Sauvageot J; Song K; Kitada S; Reed JC
Am J Pathol; 1996 May; 148(5):1567-76. PubMed ID: 8623925
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy.
Szostak MJ; Kaur P; Amin P; Jacobs SC; Kyprianou N
J Urol; 2001 Jun; 165(6 Pt 1):2126-30. PubMed ID: 11371940
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis in prostate cancer: bax correlation with stage.
Amirghofran Z; Monabati A; Gholijani N
Int J Urol; 2005 Apr; 12(4):340-5. PubMed ID: 15948719
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
Khor LY; Moughan J; Al-Saleem T; Hammond EH; Venkatesan V; Rosenthal SA; Ritter MA; Sandler HM; Hanks GE; Shipley WU; Pollack A
Clin Cancer Res; 2007 Jun; 13(12):3585-90. PubMed ID: 17575222
[TBL] [Abstract][Full Text] [Related]
9. Bax to Bcl-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer.
Matsumoto H; Wada T; Fukunaga K; Yoshihiro S; Matsuyama H; Naito K
Jpn J Clin Oncol; 2004 Mar; 34(3):124-30. PubMed ID: 15078907
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10.
Khor LY; Desilvio M; Li R; McDonnell TJ; Hammond ME; Sause WT; Pilepich MV; Okunieff P; Sandler HM; Pollack A
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):25-30. PubMed ID: 16814949
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
Rosser CJ; Reyes AO; Vakar-Lopez F; Levy LB; Kuban DA; Hoover DC; Lee AK; Pisters LL
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):1-6. PubMed ID: 12694817
[TBL] [Abstract][Full Text] [Related]
14. Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients.
Guo Y; Sigman DB; Borkowski A; Kyprianou N
Prostate; 2000 Feb; 42(2):130-6. PubMed ID: 10617870
[TBL] [Abstract][Full Text] [Related]
15. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue.
Xie X; Clausen OP; De Angelis P; Boysen M
Cancer; 1999 Sep; 86(6):913-20. PubMed ID: 10491515
[TBL] [Abstract][Full Text] [Related]
17. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
Szostak MJ; Kyprianou N
Oncol Rep; 2000; 7(4):699-706. PubMed ID: 10854529
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy.
Wootipoom V; Lekhyananda N; Phungrassami T; Boonyaphiphat P; Thongsuksai P
Gynecol Oncol; 2004 Sep; 94(3):636-42. PubMed ID: 15350352
[TBL] [Abstract][Full Text] [Related]
19. Biologic factors and response to radiotherapy in carcinoma of the cervix.
Mukherjee G; Freeman A; Moore R; Kumaraswamy ; Devi KU; Morris LS; Coleman N; Dilworth S; Prabhakaran PS; Stanley MA
Int J Gynecol Cancer; 2001; 11(3):187-93. PubMed ID: 11437923
[TBL] [Abstract][Full Text] [Related]
20. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
